INCY · Incyte Corp · Earnings Call Transcripts & Audio
$121.35
-1.85 (-1.50%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$24.75B
Shares
199.78M
Volume · Sep 30
1.62M
Avg daily vol (3M)
1.6M
Incyte Corp Earnings Call Transcripts
Quarterly earnings calls for Incyte Corp (INCY), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲1.3%
$823.30M
$112.78M
'22 Q3
22-11-01
▲7.4%
$926.70M
$28.46M
'22 Q4
23-02-07
▲10.3%
$808.67M
$21.70M
'23 Q1
23-05-02
▲4.7%
$954.61M
$203.55M
'23 Q2
23-08-01
▲11.6%
$919.02M
$171.27M
'23 Q3
23-10-31
▲9.3%
$1.01B
$201.08M
'23 Q4
24-02-13
▲8.9%
$880.89M
$169.55M
'24 Q1
24-04-30
▲9.3%
$1.04B
−$444.60M
'24 Q2
24-07-30
▲23.8%
$1.14B
$106.46M
'24 Q3
24-10-29
▲16.3%
$1.18B
$201.21M
'24 Q4
25-02-10
▲19.5%
$1.05B
$158.20M
'25 Q1
25-04-29
▲16.5%
$1.22B
$405.00M
'25 Q2
25-07-29
▲20%
$1.37B
$424.17M
'25 Q3
25-10-28
▲27.8%
$1.51B
$299.28M
'25 Q4
26-02-10
LATEST
▲20.9%
$1.27B
$303.33M
'26 Q1
26-04-28
Conference
Investor event
2026-09-16
Incyte Corp (INCY) September 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-09
Incyte Corp (INCY) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-07-28
Incyte Corp (INCY) Q2 2026 Earnings Call Transcript
Confident tone
Late-stage pipeline advancement
Jackify XR launch and core franchise
Operational execution and company transition
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Incyte Corp (INCY) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-08
Incyte Corp (INCY) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-28
Incyte Corp (INCY) Q1 2026 Earnings Call Transcript
Confident tone
Geographic and international growth
Core business expansion beyond Jakify
Pipeline and regulatory milestones
Revenue
$1.27B
▲ 20.9% YoY Diluted EPS
$1.47
▲ 83.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-11
Incyte Corp (INCY) March 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-10
Incyte Corp (INCY) Q4 2025 Earnings Call Transcript
Confident tone
2025 Financial Performance and 2026 Outlook
Pipeline Risks and Clinical Readouts
Jakafi Franchise and Jakafi XR
Revenue
$1.51B*
▲ 27.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-28
Incyte Corp (INCY) Q3 2025 Earnings Call Transcript
Confident tone
Hem/onc innovation focus (MPNs, 989, 617)
Niktimvo launch trajectory
Jakafi performance and guidance raise
Revenue
$1.37B
▲ 20% YoY Diluted EPS
$2.11
▲ 290.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-29
Incyte Corp (INCY) Q2 2025 Earnings Call Transcript
Confident tone
Pipeline catalysts (989, povorcitinib, axatilimab)
Jakafi demand outlook and IRA
Niktimvo launch
Revenue
$1.22B
▲ 16.5% YoY Diluted EPS
$2.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-29
Incyte Corp (INCY) Q1 2025 Earnings Call Transcript
Confident tone
Jakafi commercial performance and guidance raise
Financial results and operating expenses
KRAS G12D inhibitor competitive landscape
Revenue
$1.05B
▲ 19.5% YoY Diluted EPS
$0.80
▲ 6.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-10
Incyte Corp (INCY) Q4 2024 Earnings Call Transcript
Confident tone
Jakafi (ruxolitinib) performance and guidance
Opzelura growth and pediatric atopic dermatitis launch
2025 pipeline catalysts and pivotal readouts
Revenue
$1.18B*
▲ 16.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-29
Incyte Corp (INCY) Q3 2024 Earnings Call Transcript
Confident tone
Opzelura growth and geographic expansion
Jakafi commercial performance and guidance raise
CDK2 inhibitor competitive positioning
Revenue
$1.14B
▲ 23.8% YoY Diluted EPS
$0.54
▼ 28.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-30
Incyte Corp (INCY) Q2 2024 Earnings Call Transcript
Confident tone
Opzelura growth and expansion
Jakafi commercial performance and guidance
Pipeline transformation and prioritization
Revenue
$1.04B
▲ 9.3% YoY Diluted EPS
$-2.04
▼ 326.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-30
Incyte Corp (INCY) Q1 2024 Earnings Call Transcript
Positive tone
Jakafi performance
Opzelura growth
Pipeline launches by 2030
Revenue
$880.89M
▲ 8.9% YoY Diluted EPS
$0.75
▲ 650% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-13
Incyte Corp (INCY) Q4 2023 Earnings Call Transcript
Confident tone
Opzelura launch momentum
Jakafi commercial performance and 2024 guidance
Pipeline and ten high-impact launches by 2030
Revenue
$1.01B*
▲ 9.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-31
Incyte Corp (INCY) Q3 2023 Earnings Call Transcript
Revenue
$919.02M
▲ 11.6% YoY Diluted EPS
$0.76
▲ 52% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Incyte Corp (INCY) Q2 2023 Earnings Call Transcript
Revenue
$954.61M
▲ 4.7% YoY Diluted EPS
$0.90
▲ 25% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Incyte Corp (INCY) Q1 2023 Earnings Call Transcript
Revenue
$808.67M
▲ 10.3% YoY Diluted EPS
$0.10
▼ 41.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-07
Incyte Corp (INCY) Q4 2022 Earnings Call Transcript
Revenue
$926.70M*
▲ 7.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Incyte Corp (INCY) Q3 2022 Earnings Call Transcript
Revenue
$823.30M
▲ 1.3% YoY Diluted EPS
$0.50
▼ 39% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Incyte Corp (INCY) Q2 2022 Earnings Call Transcript
Revenue
$911.40M
▲ 29.1% YoY Diluted EPS
$0.72
▲ 7.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Incyte Corp (INCY) Q1 2022 Earnings Call Transcript
Revenue
$733.24M
▲ 21.3% YoY Diluted EPS
$0.17
▼ 29.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-08
Incyte Corp (INCY) Q4 2021 Earnings Call Transcript
Revenue
$862.85M*
▲ 9.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Incyte Corp (INCY) Q3 2021 Earnings Call Transcript
Revenue
$812.99M
▲ 31% YoY Diluted EPS
$0.82
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Incyte Corp (INCY) Q2 2021 Earnings Call Transcript
Revenue
$705.71M
▲ 2.6% YoY Diluted EPS
$0.67
▼ 49.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Incyte Corp (INCY) Q1 2021 Earnings Call Transcript
Revenue
$604.72M
▲ 6.4% YoY Diluted EPS
$0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-09
Incyte Corp (INCY) Q4 2020 Earnings Call Transcript
Revenue
$789.51M
▲ 36.3% YoY Diluted EPS
$0.68
▲ 33.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Incyte Corp (INCY) Q3 2020 Earnings Call Transcript
Revenue
$620.64M
▲ 12.5% YoY Diluted EPS
$-0.07
▼ 111.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Incyte Corp (INCY) Q2 2020 Earnings Call Transcript
Revenue
$688.04M
▲ 29.8% YoY Diluted EPS
$1.32
▲ 175% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Incyte Corp (INCY) Q1 2020 Earnings Call Transcript
Revenue
$568.51M
▲ 14.2% YoY Diluted EPS
$-3.33
▼ 808.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-13
Incyte Corp (INCY) Q4 2019 Earnings Call
Revenue
$579.39M
▲ 9.6% YoY Diluted EPS
$0.51
▲ 59.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–32 of 32 earnings calls
Key facts
CIK
879169
CUSIP
45337C102
13F (30d)
17 filings
13 filers
Visit website
Investor relations